SLNO SOLENO THERAPEUTICS INC
FY2025 10-K
SOLENO THERAPEUTICS INC (SLNO) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Biopharmaceutical company developing and commercializing novel therapeutics for rare diseases, with initial focus on Prader-Willi syndrome (PWS)
- • New product: FDA approval and first commercial sales of VYKAT XR (diazoxide choline extended-release tablets) for hyperphagia in PWS patients aged 4 and older in March 2025
Management Discussion & Analysis
- • No revenue or YoY change figures disclosed
- • No profitability or operating margin data provided
Risk Factors
- • Regulatory risk: FDA approval of VYKAT XR in March 2025 triggered contingent payments of $7.0 million due Q1 2026
- • Macroeconomic exposure: $50 million outstanding loan with Oxford at 1-month SOFR + 5.50% interest, with $100 million more contingent on mutual consent
Financial SummaryXBRL
Revenue
$190M
Net Income
$21M
Operating Margin
4.9%
Net Margin
11.0%
ROE
4.6%
Total Assets
$564M
EPS (Diluted)
$0.39
Operating Cash Flow
$47M
Source: XBRL data from SOLENO THERAPEUTICS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SOLENO THERAPEUTICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.